Basimglurant

Synonyms: RG7090; RO4917523
Basimglurant (RG7090; RO4917523) 是一种选择性、口服有效且可穿透血脑屏障的代谢型谷氨酸受体 5 (mGluR5) 负性变构调节剂,其对 [³H]-ABP688 (MS-T13256) 的 Ki 为 1.4 nM、对 [³H]-MPEP (MS-X10413) 的 Ki 为 35.6 nM,可抑制 mGlu5 介导的信号通路和受体组成型活性、调节伏隔核多巴胺水平,从而发挥抗焦虑、类抗抑郁、镇痛和促觉醒作用,并改变非快速眼动睡眠的 δ 波功率,可用于抑郁症、脆性 X 综合征、焦虑症等研究。
产品编号: MS-U47211 纯度: 98.0% CAS No.: 802906-73-6 分子式: C18H13ClFN3 分子量: 325.77
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Basimglurant (RG7090; RO4917523) 是一种选择性、口服有效且可穿透血脑屏障的代谢型谷氨酸受体 5 (mGluR5) 负性变构调节剂,其对 [³H]-ABP688 (MS-T13256) 的 Ki 为 1.4 nM、对 [³H]-MPEP (MS-X10413) 的 Ki 为 35.6 nM,可抑制 mGlu5 介导的信号通路和受体组成型活性、调节伏隔核多巴胺水平,从而发挥抗焦虑、类抗抑郁、镇痛和促觉醒作用,并改变非快速眼动睡眠的 δ 波功率,可用于抑郁症、脆性 X 综合征、焦虑症等研究。

生物实验数据

生物活性 Basimglurant (RG7090; RO4917523) is a selective, orally active, blood-brain barrier-penetrant negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5) with a Ki of 1.4 nM (against [³H]-ABP688 (MS-T13256)) and 35.6 nM (against [³H]-MPEP (MS-X10413)); it inhibits mGlu5-mediated signaling pathways and receptor constitutive activity, modulates accumbal dopamine levels, exerts anxiolytic, antidepressant-like, analgesic, and wake-promoting effects, and alters delta wave power during non-rapid eye movement sleep, and can be used for research on depression, fragile X syndrome, anxiety disorders, and other conditions.
IC50 & Target mGluR5:1.1 nM (Kd)
体外研究
(In Vitro)

Basimglurant 在大鼠肝微粒体中代谢稳定性较低 (11 μL/min/mg),在人肝微粒体中稳定性良好 (CL <10 μL/min/mg)。
Basimglurant 在胚胎干细胞试验中无致畸潜力。
Basimglurant 可强效抑制 [3H]-MPEP 与人、小鼠及大鼠 mGlu5 受体的结合,其对三种受体的 Ki 值分别为 35.6 nM、29.5 nM 和 33.2 nM。
Basimglurant 可强效抑制人、小鼠和大鼠 mGlu5 表达型 HEK293 细胞中由使 Quisqualate 诱导的钙动员,其 IC50 值分别为 7.0 nM、8.88 nM 和 7.48 nM。
Basimglurant 可强效抑制 Quisqualate 诱导的表达人、小鼠和大鼠 mGlu5 的 HEK293 细胞中 IP 的积累,其 IC50 值分别为 5.85 nM、4.98 nM 和 5.93 nM;同时它可作为人 mGlu5 受体的反向激动剂,对应的 IC50 为 38.1 nM。

体内研究
(In Vivo)

Basimglurant (1-3 mg/kg;腹腔注射,每日给药,连续 21 天) 在慢性温和应激诱导快感缺失的大鼠中表现出显著的类抗抑郁活性。
Basimglurant (10-30 mg/kg;口服;24 小时内给药 3 次) 可在大鼠强迫游泳实验中产生类抗抑郁作用。
Basimglurant (1-30 mg/kg;口服;单次给药) 可在大鼠中诱导与典型抗抑郁药高度相似的脑活动模式。
Basimglurant (0.03-0.3 mg/kg;口服;单次给药) 在大鼠 Vogel 冲突试验中表现出类抗焦虑活性。
Basimglurant (0.01-1 mg/kg;口服;单次给药) 在小鼠应激诱导的体温过高试验中发挥抗焦虑作用。
Basimglurant (0.3-1 mg/kg;口服;单次给药) 在大鼠条件性情绪反应试验中表现出类抗焦虑活性。
Basimglurant (0.1-1 mg/kg;口服;单次给药) 在大鼠恐惧增强惊跳实验中产生类抗焦虑作用。
Basimglurant (10 mg/kg;口服;单次给药) 在小鼠福尔马林诱导疼痛模型的晚期阶段表现出镇痛活性。
Basimglurant (0.1-10 mg/kg;皮下注射;单次给药) 可剂量依赖性地抑制坐骨神经结扎大鼠的冷异常痛觉。
Basimglurant (0.03-0.3 mg/kg;静脉注射;单次给药) 可剂量依赖性地提高麻醉大鼠的排尿阈值容量。
Basimglurant (0.01-0.03 mg/kg;静脉注射;单次给药) 可强效降低麻醉大鼠的膀胱收缩频率。
basimglurant (0.03-0.3 mg/kg;口服;每日一次;连续 5 天) 可在挪威大鼠的活动暗期产生剂量依赖性的促觉醒作用,减少快速眼动 (REM) 睡眠和非快速眼动 (non-REM) 睡眠,延长睡眠潜伏期,并增强非快速眼动睡眠的 δ 波功率。

Animal Model: Wistar rats (male, 350 g, chronic mild stress-induced anhedonia model with unilateral ventral tegmental area electrode implantation)
Dosage: 1 mg/kg; 3 mg/kg
Administration: i.p.; daily; 21 days
Result: Reduced the anhedonia index by -72% (day 35), -53% (day 39), and -64% (day 42) compared to vehicle-treated stressed rats at 3 mg/kg, normalizing values to pre-stress baseline levels.
Reduced the anhedonia index significantly with consistent effects across the treatment period at 1 mg/kg.
Had no significant effect on anhedonia index in unstressed rats.
Animal Model: Wistar rats (male, 350 g, chronic mild stress-induced anhedonia model with unilateral ventral tegmental area electrode implantation)
Dosage: 1 mg/kg; 3 mg/kg
Administration: i.p.; daily; 21 days
Result: Reduced the anhedonia index by -72% (day 35), -53% (day 39), and -64% (day 42) compared to vehicle-treated stressed rats at 3 mg/kg, normalizing values to pre-stress baseline levels.
Reduced the anhedonia index significantly with consistent effects across the treatment period at 1 mg/kg.
Had no significant effect on anhedonia index in unstressed rats.
Animal Model: Sprague Dawley rats (male, 190-210 g, Vogel conflict drinking test model)
Dosage: 0.03 mg/kg; 0.1 mg/kg; 0.3 mg/kg
Administration: p.o.; single dose; 1 hour pre-test
Result: Increased punished drinking time by +165% at 0.03 mg/kg, with further increases at higher doses, reaching significance at all tested doses compared to vehicle.
Animal Model: Fischer F344 rats (male, ~250 g, fMRI-based brain activity profiling model)
Dosage: 1 mg/kg; 10 mg/kg; 30 mg/kg
Administration: p.o.; single dose; 1 hour pre-fMRI imaging
Result: Increased perfusion in the dorsal striatum and decreased perfusion in the medial prefrontal cortex, dorsal hippocampus, thalamus, hypothalamus, septum, nucleus accumbens, ventral pallidum, and entorhinal piriform cortex at 1 mg/kg.
Amplified the perfusion changes observed at 1 mg/kg at 10 mg/kg.
Showed a pattern match coefficient (PMC) of >0.71 compared to prototypical antidepressants including duloxetine, reboxetine, imipramine, bupropion, and electroconvulsive treatment (ECT) at 1 and 10 mg/kg.
Surpassed the root mean square (RMS) response strength of ECT and standard antidepressants at 30 mg/kg at 1 and 10 mg/kg.
Animal Model: Sprague Dawley rats (male, 190-210 g, Vogel conflict drinking test model)
Dosage: 0.03 mg/kg; 0.1 mg/kg; 0.3 mg/kg
Administration: p.o.; single dose; 1 hour pre-test
Result: Increased punished drinking time by +165% at 0.03 mg/kg, with further increases at higher doses, reaching significance at all tested doses compared to vehicle.
Animal Model: NMRI mice (male, ~22 g, stress-induced hyperthermia model)
Dosage: 1 mg/kg; 10 mg/kg; 30 mg/kg
Administration: p.o.; single dose; 1 hour pre-test
Result: Reduced stress-induced hyperthermia by -48% at 0.01 mg/kg, -73% at 0.1 mg/kg, and -145% at 1 mg/kg compared to vehicle, with all doses producing significant effects.
Animal Model: Sprague Dawley rats (male, 350 g, conditioned emotional response model)
Dosage: 0.03 mg/kg; 0.1 mg/kg
Administration: p.o.; single dose; 1 hour pre-test
Result: Increased the suppression ratio by +567% at 0.3 mg/kg and +583% at 1 mg/kg compared to vehicle, indicating reduced fear response.
Animal Model: Sprague Dawley rats (male, 225-287 g, fear-potentiated startle model)
Dosage: 0.03 mg/kg; 0.1 mg/kg
Administration: p.o.; single dose; 1 hour pre-test
Result: Reduced fear-potentiated startle amplitude by -53% at 0.1 mg/kg and -94% at 1 mg/kg compared to vehicle, with significant effects at both doses.
Animal Model: NMRI mice (male, 24-30 g, formalin-induced paw licking model, late phase)
Dosage: 1 mg/kg; 10 mg/kg
Administration: p.o.; single dose; 40 minutes pre-formalin injection
Result: Reduced paw licking time by -91% (non-significant) at 1 mg/kg and -95% (significant) at 10 mg/kg compared to vehicle in the late phase of formalin-induced pain.
Had no significant effect in the early phase at any tested dose.
Animal Model: Sprague Dawley rats (female, 100-250 g, Bennett model of cold allodynia with sciatic nerve constriction injury)
Dosage: 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: s.c.; single dose; 60 minutes pre-test
Result: Increased the inhibition rate of cold allodynia by 28% at 0.1 mg/kg, 37% at 0.3 mg/kg, 50% at 1 mg/kg, 39% at 3 mg/kg, and 58% at 10 mg/kg compared to vehicle.
Produced significant effects at all doses, with maximal efficacy comparable to morphine (64% inhibition rate) and duloxetine (56% inhibition rate).
Animal Model: Sprague Dawley rats (female, 200-250 g, volume-induced micturition reflex model with cannulated bladders, anesthetized)
Dosage: 0.03 mg/kg; 0.3 mg/kg
Administration: i.v.; single dose
Result: Increased the micturition threshold volume by +27% at 0.03 mg/kg and +166.9% at 0.3 mg/kg compared to baseline, with significant effects at both doses.
Animal Model: Sprague Dawley rats (female, 200-250 g, isovolumetric bladder contraction model with cannulated bladders, anesthetized)
Dosage: 0.01 mg/kg; 0.03 mg/kg
Administration: i.v.; single dose
Result: Reduced bladder contraction frequency by -88.5% at 0.01 mg/kg and -79.9% at 0.03 mg/kg compared to vehicle, with maximal effects comparable at both doses.
性状 固体
颜色 Off-white to yellow

化学信息

分子量 325.77
分子式 C18H13ClFN3
CAS No. 802906-73-6
别名 RG7090; RO4917523

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.14 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 33.33 mg/mL (102.31 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.0697 mL15.3483 mL30.6965 mL76.7413 mL
5 mM0.6139 mL3.0697 mL6.1393 mL15.3483 mL
10 mM0.3070 mL1.5348 mL3.0697 mL7.6741 mL
15 mM0.2046 mL1.0232 mL2.0464 mL5.1161 mL
20 mM0.1535 mL0.7674 mL1.5348 mL3.8371 mL
25 mM0.1228 mL0.6139 mL1.2279 mL3.0697 mL
30 mM0.1023 mL0.5116 mL1.0232 mL2.5580 mL
40 mM0.0767 mL0.3837 mL0.7674 mL1.9185 mL
50 mM0.0614 mL0.3070 mL0.6139 mL1.5348 mL
60 mM0.0512 mL0.2558 mL0.5116 mL1.2790 mL
80 mM0.0384 mL0.1919 mL0.3837 mL0.9593 mL
100 mM0.0307 mL0.1535 mL0.3070 mL0.7674 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础